Who keeps citing retracted work?
The retracted papers still cited most often as support, and the journals and authors whose papers do it most. How each list was checked, and replies from the people named. Every entry is an AI reading, rung 2 on our severity scale, pending human review. Census data as of 14 Oct 2026; corrections through 9 Nov 2026.
The retracted papers most often still cited as support.
Ranked by how many citations, made after the retraction, use the paper as support for a claim.
Together, these 10 papers are cited as support by 482 papers published after their retraction, among them 13 systematic reviews or meta-analyses and 13 trials; 164 of those acknowledge grants. In turn, 14,916 later papers cite those 482, among them 466 systematic reviews or meta-analyses, 249 trials and 7 guidelines. This measures reach, not harm. Each paper below says what it claimed, why its retraction matters and what it reached.
| # | Retracted paper | Cited as support after retraction | Second reading |
|---|---|---|---|
| 1 | Visfatin: a protein secreted by visceral fat that mimics the effects of insulinFukuhara A et al., Science 2004. Retracted 2007: An Osaka University research integrity committee examined the insulin-receptor experiments and the university recommended retraction; the authors "continue to stand by our conclusions" but found "not all preparations of visfatin bind to and activate the insulin receptor".
| 104of 314 judged (33.1%) | 9 of 14its findings |
| 2 | Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19Mehra MR et al., N Engl J Med 2020. Retracted 2020: The authors could not get the raw data audited, so they were "unable to validate the primary data sources".
| 80of 365 judged (21.9%) | 9 of 12its findings |
| 3 | Predictive validity of a medication adherence measure in an outpatient settingMorisky DE et al., J Clin Hypertens (Greenwich) 2008. Retracted 2023: An independent statistical review found the results "misleading due to issues regarding the sensitivity and specificity" of the adherence measure.Most citations use the MMAS-8 adherence questionnaire and its cut-offs.
| 56of 183 judged (30.6%) | 11 of 14its questionnaire |
| 4 | Association Between Physician Burnout and Patient Safety, Professionalism, and Patient Satisfaction: A Systematic Review and Meta-analysisPanagioti M et al., JAMA Intern Med 2018. Retracted 2020: A University of Manchester panel "found no evidence of intentional fabrication" but, because of flaws in the review process, "cannot confirm that the results of the meta-analysis are wholly valid".
| 53of 203 judged (26.1%) | 11 of 13its findings |
| 5 | The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytesXu C et al., J Cell Sci 2007. Retracted 2011: The authors retracted it over "the misuse and re-use of western blot bands" in Figures 3 and 4A, which broke the journal's editorial policy.
| 51of 98 judged (52.0%) | 11 of 14its findings |
| 6 | Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during agingWenz T et al., Proc Natl Acad Sci U S A 2009. Retracted 2016: A University of Cologne investigation "concluded that there was scientific misconduct": blots in Figs. 2D and 3B also appear in an unrelated paper, and a tubulin blot is duplicated.
| 31of 60 judged (51.7%) | 13 of 13its findings |
| 7 | circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 familyChen L et al., Oncogene 2017. Retracted 2019: The authors found "serious errors in Figs. 5c and 7b, resulting from the data collection process" and are no longer confident in the conclusions.
| 30of 94 judged (31.9%) | 9 of 13its findings |
| 8 | Spontaneous human adult stem cell transformationRubio D et al., Cancer Res 2005. Retracted 2010: The authors could not reproduce some of the reported transformation events and "suspect the phenomenon is due to a cross-contamination artifact"; five of the seven authors agreed to the retraction.
Reply from the senior author, received 22 Oct 2026Dr Bernad says the 2005 paper was the first report of an apparent spontaneous transformation of mesenchymal stem cells in culture, at a time when these cells were being tested in many cell therapies, so it had a large impact on the field. Soon after publication his group found that the main conclusion could not be reproduced and was most probably due to a very small number of contaminating transformed cells that overgrew the cultures. He says the group contacted Cancer Research to offer a retraction; the journal preferred a short notice (de la Fuente et al., 2010) to the longer one they wrote. He says the group approached the journal soon after finding the result could not be reproduced. He did not give the date of that contact by 28 October (the notice was published in August 2010). He proposed a note for later authors, printed below as he wrote it, and points to his group's later work on long-term culture of these cells. Soon after publication (Rubio et al., 2005) we realized that the main conclusion was non reproducible and that the putative spontaneous transformation was most probably due to a highly minoritarian number of a transformed cell line.Statement from the senior author, printed as written: Our response: The retraction notice was published in Cancer Research in August 2010 (doi:10.1158/0008-5472.CAN-10-2451). His group's later papers: Estrada JC et al., Cell Death Dis 2013 (replicative senescence of these cells in long-term culture is closely linked to aneuploidy) and Sepúlveda JC et al., Stem Cells 2014 (senescence abrogates their therapeutic potential in a mouse model of lethal endotoxemia). The entry stands: the citations counted were made after the retraction and use the paper as support.Changes since our letter:
| 26of 131 judged (19.8%)each one read twice | 12 of 14its findings |
| 8 | A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cellsHattori Y et al., Diabetologia 2010. Retracted 2011: Retracted "following the discovery of redundant publication": part of Figure 2c had been published before in Cardiovascular Research.
| 26of 54 judged (48.1%)each one read twice | 0 of 0its findings |
| 10 | Selective killing of cancer cells by a small molecule targeting the stress response to ROSRaj L et al., Nature 2011. Retracted 2018: Problems with Fig. 1d and Supplementary Fig. 31b, and missing original data, "raise concerns regarding the integrity of the figures"; five authors disagree with the retraction.
| 25of 93 judged (26.9%)each one read twice | 13 of 15its findings |
Second reading: of up to 15 citations drawn at random and read again (fewer where a later full-text check took one out of scope), how many cite the paper as support, and what they use it for. The sample was drawn before the full read; where the full read changed a citation's label, the final label is the one counted here and in second-reading.csv. Ties share a place. Each reason quotes or closely follows the retraction notice; where we have not yet read a notice, we say so.
Every paper on this list, and each paper near the last place, was read in full on 23 October: each citation counted as "cited as support" was checked against the citing paper's full text, and those that turned out to be passing mentions, warnings about the retraction, citations of the retraction notice or of something else, or that credit the paper with something it does not report, no longer count. For the papers at and just below the last places, each citation was read twice, independently, and a third reading settled the 11 on which the first two disagreed. These are AI readings. The papers left off after reading were judged on their second reading, not read in full.
Left off after reading
These papers would make the list on the count alone, but reading them showed the citations cite something the retraction does not touch, for example a tool or method in the paper that still works.
| Retracted paper | Support | Why it is left off |
|---|---|---|
| An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virusVoinnet O et al., Plant J 2003. Retracted 2015: Image duplications in Figure 3b and in loading-control lanes of Figures 2g, 3a, 4e and 4f; the authors "accept that integrity of the scientific literature is compromised by the data manipulation".paper · retraction notice · every citation | 167of 246 | Citations use the p19 lab tool the paper describes, which still works (14 of 15 read). It was retracted over duplicated figures. |
| Global Increase in Breast Cancer Incidence: Risk Factors and Preventive MeasuresKashyap D et al., Biomed Res Int 2022. Retracted 2023: The publisher found "evidence of systematic manipulation of the publication and peer-review process" and cannot "vouch for the reliability or integrity" of the article.paper · retraction notice · every citation | 29of 143 | A review: citations use its summary figures, which come from other published sources. |
The journals whose papers most often cite retracted work as support.
Two ways to rank: the count favours large journals, the share is fairer to small ones. The census reads open-access papers, so journals that publish everything open access are counted in full and others in part: large open-access journals rank high on counts partly because more of their papers could be read. Compare journals by the share table. These are the journals that published the citing papers, not the retracted ones.
Why it matters: a journal's editors and peer reviewers are the last check before a paper is published. A reference to a retracted paper, used as support, can be caught at that stage by checking the reference list against a list of retractions.
Most citations of retracted work as support
| # | Citing journal | Cited as support | Second reading |
|---|---|---|---|
| 1 | Int J Mol Sci609 papers cite retracted work as supportThey cite 561 different retracted papers as support. Most often: Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging (retracted 2016; 4 citations); 14 others have 3 citations each. | 653653 of 1,547 judged (42.2%) | 9 of 9 |
| 2 | Sci Rep568 papers cite retracted work as supportThey cite 521 different retracted papers as support. Most often: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin (retracted 2007; 4 citations) and Effect of zinc nanoparticles seed priming and foliar application on the growth and physio-biochemical indices of spinach (Spinacia oleracea L.) under salt stress (retracted 2022; 4 citations). | 580580 of 1,731 judged (33.5%) | 7 of 10 |
| 3 | PLoS One486 papers cite retracted work as supportThey cite 420 different retracted papers as support. Most often: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin (retracted 2007; 9 citations) and The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes (retracted 2011; 7 citations). | 496496 of 1,586 judged (31.3%) | 7 of 8 |
| 4 | Front Pharmacol320 papers cite retracted work as supportThey cite 324 different retracted papers as support. Most often: Anti-apoptosis mechanism of triptolide based on network pharmacology in focal segmental glomerulosclerosis rats (retracted 2020; 3 citations); 22 others have 2 citations each. | 348348 of 680 judged (51.2%) | 8 of 10 |
| 5 | Front Immunol299 papers cite retracted work as supportThey cite 277 different retracted papers as support. Most often: CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation (retracted 2011; 7 citations) and Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance (retracted 2013; 7 citations). | 326326 of 720 judged (45.3%) | 10 of 10 |
| 6 | Front Oncol269 papers cite retracted work as supportThey cite 290 different retracted papers as support. Most often: circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family (retracted 2019; 3 citations), Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/B-catenin signaling pathway (retracted 2019; 3 citations), KIF20A silence inhibits the migration, invasion and proliferation of non-small cell lung cancer and regulates the JNK pathway (retracted 2020; 3 citations) and m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis (retracted 2023; 3 citations). | 313313 of 629 judged (49.8%) | 8 of 91 of the papers read again has since been retracted (PMC10580988) |
| 7 | Heliyon275 papers cite retracted work as supportThey cite 287 different retracted papers as support. Most often: Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma (retracted 2021; 3 citations); 8 others have 2 citations each. | 297297 of 648 judged (45.8%) | 7 of 91 of the papers read again has since been retracted (PMC11033103) |
| 8 | Cancers (Basel)209 papers cite retracted work as supportThey cite 214 different retracted papers as support. Most often: IL-6 Secreted by Cancer-associated Fibroblasts Induces Tamoxifen Resistance in Luminal Breast Cancer (retracted 2014; 5 citations) and MicroRNA-221/222 Negatively Regulates Estrogen Receptor alpha and is Associated with Tamoxifen Resistance in Breast Cancer (retracted 2016; 4 citations). | 238238 of 544 judged (43.8%) | 6 of 9 |
| 9 | Molecules191 papers cite retracted work as supportThey cite 182 different retracted papers as support. Most often: Selective killing of cancer cells by a small molecule targeting the stress response to ROS (retracted 2018; 5 citations), Cyclodextrin-complexed Curcumin Exhibits Anti-inflammatory and Antiproliferative Activities Superior to Those of Curcumin Through Higher Cellular Uptake (retracted 2016; 3 citations), Updated knowledge about polyphenols: functions, bioavailability, metabolism, and health (retracted 2015; 3 citations) and Synthesis, characterization and catalytic activity of silver nanoparticles using Tribulus terrestris leaf extract (retracted 2016; 3 citations). | 203203 of 488 judged (41.6%) | 8 of 10 |
| 10 | Front Cell Dev Biol134 papers cite retracted work as supportThey cite 154 different retracted papers as support. Most often: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (retracted 2022; 3 citations); 7 others have 2 citations each. | 163163 of 295 judged (55.3%) | 8 of 8 |
Highest share as support, among journals with 100+ judged citations
| # | Citing journal | Share cited as support | Second reading |
|---|---|---|---|
| 1 | Front Mol Biosci57 papers cite retracted work as supportThey cite 69 different retracted papers as support. Most often: Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer (retracted 2021; 2 citations). | 60.3%70 of 116 judged (60.3%) | 9 of 9 |
| 2 | Cell Commun Signal54 papers cite retracted work as supportThey cite 63 different retracted papers as support. Most often: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA (retracted 2023; 2 citations). | 58.2%64 of 110 judged (58.2%) | 8 of 8 |
| 3 | Noncoding RNA Res42 papers cite retracted work as supportThey cite 65 different retracted papers as support. | 57.5%65 of 113 judged (57.5%) | 9 of 9 |
| 4 | Front Cell Dev Biol134 papers cite retracted work as supportThey cite 154 different retracted papers as support. Most often: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (retracted 2022; 3 citations); 7 others have 2 citations each. | 55.3%163 of 295 judged (55.3%) | 8 of 8 |
| 5 | Cancer Cell Int116 papers cite retracted work as supportThey cite 138 different retracted papers as support. Most often, 5 papers tie at 2 citations each, among them Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a (retracted 2023; 2 citations) and circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family (retracted 2019; 2 citations). | 55.2%143 of 259 judged (55.2%) | 7 of 9 |
| 6 | Onco Targets Ther62 papers cite retracted work as supportThey cite 61 different retracted papers as support. Most often: Baicalein inhibits proliferation and migration of bladder cancer cell line T24 by down-regulation of microRNA-106 (retracted 2020; 2 citations). | 53.9%62 of 115 judged (53.9%) | 6 of 71 of the papers read again has since been retracted (PMC6885654) |
| 7 | Bioengineered76 papers cite retracted work as supportThey cite 79 different retracted papers as support. Most often: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway (retracted 2020; 2 citations), LncRNA MALAT1 regulates sepsis-induced cardiac inflammation and dysfunction via interaction with miR-125b and p38 MAPK/NFκB (retracted 2021; 2 citations) and Circ_0008035 contributes to cell proliferation and inhibits apoptosis and ferroptosis in gastric cancer via miR-599/EIF4A1 axis (retracted 2021; 2 citations). | 52.9%82 of 155 judged (52.9%) | 8 of 8 |
| 8 | Front Pharmacol320 papers cite retracted work as supportThey cite 324 different retracted papers as support. Most often: Anti-apoptosis mechanism of triptolide based on network pharmacology in focal segmental glomerulosclerosis rats (retracted 2020; 3 citations); 22 others have 2 citations each. | 51.2%348 of 680 judged (51.2%) | 8 of 10 |
| 9 | Discov Oncol92 papers cite retracted work as supportThey cite 105 different retracted papers as support. Most often: Exosomal long non-coding RNA UCA1 functions as growth inhibitor in esophageal cancer (retracted 2022; 2 citations). | 51.0%106 of 208 judged (51.0%) | 8 of 9 |
| 10 | Front Neurosci48 papers cite retracted work as supportThey cite 49 different retracted papers as support. Most often: Temporal activation of anti- and pro-apoptotic factors in human gingival fibroblasts infected with the periodontal pathogen, Porphyromonas gingivalis: potential role of bacterial proteases in host signalling (retracted 2019; 2 citations) and Transcutaneous vagus nerve stimulation (tVNS) enhances response selection during action cascading processes (retracted 2022; 2 citations). | 50.5%51 of 101 judged (50.5%) | 8 of 9 |
Second reading: 10 support citations per journal, drawn at random and read again. Later taken out of the samples: citations of work retracted for a reason that does not touch the results; citations that turned out to come before the retraction once the dates were checked; citations a full-text check found do not point to the retracted paper; and citations a later full-text check took out of scope. Across the lists' scope, 40.2% of citations are support (the census headline, which also counts papers PubMed does not yet link to a notice, is 40.7%). With 100 to 300 citations, a share can be off by several points either way, so close places in the second table are not real differences.
The authors whose papers most often cite retracted work as support.
This counts citations, not intent. It does not say anyone acted dishonestly, and it does not judge whether a review's conclusions still stand: most of these citations sit in review articles that sum up many earlier studies, often in a table, and a co-author may have written that part.
Why it matters: readers trust a review to sum up sound evidence. A retracted study counted as support can carry an unreliable result into the review, and from there into the work that cites the review.
| # | Author | Papers citing retracted work as support | Rate | Reviews | Retracted papers cited |
|---|---|---|---|---|---|
| 1 | Mohammad TaheriORCID 0000-0001-8381-0591Co-wrote 22 of them with Bashdar Mahmud Hussen and 21 of them with Soudeh Ghafouri-Fard | 24of 26 found by the census | 10.5%of 228 tagged papers | 23 | 34 |
The 24 papers and 34 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
| |||||
| 2 | Bashdar Mahmud HussenORCID 0000-0003-1060-6527Co-wrote 22 of them with Mohammad Taheri and 19 of them with Soudeh Ghafouri-Fard | 22of 24 found by the census | 17.7%of 124 tagged papers | 21 | 32 |
The 22 papers and 32 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
| |||||
| 2 | Soudeh Ghafouri-FardORCID 0000-0002-0223-499XCo-wrote 21 of them with Mohammad Taheri and 19 of them with Bashdar Mahmud Hussen | 22of 24 found by the census | 8.2%of 268 tagged papers | 21 | 28 |
The 22 papers and 28 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
| |||||
| 4 | Michael R HamblinORCID 0000-0001-6431-4605 | 9of 9 found by the census | 4.9%of 184 tagged papers | 9 | 34 |
The 9 papers and 34 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
Reply from the author, received 22 Oct 2026Dr Hamblin says he has never knowingly cited a retracted paper and finds it hard to believe that anyone would. The papers in our letter all came from his collaborators in Iran, where internet access is sporadic, unreliable and slow, so researchers build a reference library when they have access and write from it later; a paper retracted after the library was built would not show as retracted, which he says explains our findings. He said none of these citations contains the word "retracted", though our letter said one reference list marked a work retracted. I have never knowingly cited a retracted paper and frankly I find it difficult to believe that anybody would knowingly do thisOur response: He was right about the one item our letter marked: its reference carries a link to the retraction notice, most likely added during publication. For every author, such items now sit apart under their own heading, with a note that publishers often add these links and labels, so they do not show that the authors knew. The other citations stay counted, because the reviews were published after the retractions.Changes since our letter:
| |||||
| 5 | Javad Sharifi-RadORCID 0000-0002-7301-8151 | 8of 8 found by the census | 3.1%of 262 tagged papers | 8 | 8 |
The 8 papers and 8 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
| |||||
| 6 | Abdelhakim BouyahyaORCID 0000-0001-9317-1631 | 7of 8 found by the census | 4.9%of 142 tagged papers | 7 | 9 |
The 7 papers and 10 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
| |||||
| 7 | Anupam BishayeeORCID 0000-0001-9159-960X | 6of 8 found by the census | 6.9%of 87 tagged papers | 4 | 6 |
The 6 papers and 6 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
| |||||
| 7 | Meysam MoghbeliORCID 0000-0001-9680-0309 | 6of 7 found by the census | 18.2%of 33 tagged papers | 6 | 10 |
The 6 papers and 10 citations
Reply from the author, received 22 Oct 2026In two replies, Dr Moghbeli confirms that the citations are correct. He says each review was finished and first submitted before the cited papers were retracted. In his second reply he adds that the six reviews were submitted, rejected and passed from journal to journal over long periods, often through Springer's transfer to the next journal it suggested, and that the retractions came during those transfers. Once a manuscript is under review, authors cannot change it unless the journal sends it back, and journals did not then check references for retractions as they do now; so he says authors cannot find such references unless the journal checks them and asks for a correction, and that such citations are inevitable in reviews with hundreds of references that pass through several journals. He says the retracted references, 11 of the 1,546 in the seven reviews, have no significant negative effect on the reviews' topics or conclusions. He also said the first item, Roberts JT et al. (Ann Oncol 2006), is not retracted and has no retraction notice. When we wrote, prepared, and submitted these review manuscripts, the cited papers were not yet retracted.Our response: The record he checked is the original 2005 trial in J Clin Oncol, which is not retracted; the Ann Oncol 2006 paper was retracted in 2011 as a redundant publication of it, and had already been left out under the rule for duplicates. His timelines match the journal records and the notices and are printed beside each review; those citations stay counted, because the reviews were published after the retractions. His second reply explains how the manuscripts moved between journals; it changes no entry.Changes since our letter:
| |||||
| 7 | Amirhossein SahebkarORCID 0000-0002-8656-1444 | 6of 6 found by the census | 4.2%of 144 tagged papers | 6 | 9 |
The 6 papers and 9 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
Reply from the author, received 21 Oct 2026Dr Sahebkar says a retraction is not a single verdict on a paper: notices range from fabricated data to duplicate publication, authorship disputes or a problem in one figure unrelated to the result being cited, and COPE guidance recommends citing retracted work with its status clearly marked. Whether a citation is a problem depends on whether the reason for retraction touches the statement it supports and whether the citing paper's conclusion rests on it, which a count of citations cannot answer. All seven papers in our letter are reviews of hundreds of sources, and he says none of their conclusions depends on the retracted papers. He asks that authors be compared by rates normalised by their total publications and cited references, not ranked by absolute counts, since a ranking by count is led by the authors who publish most. He was given the opportunity to send a direct response for publication instead of this summary.Our response: Two of his points changed the lists for every author: the author list now shows a rate beside each count (for him, 6 of 144 papers, 4.2%), and citations of work retracted for reasons that do not touch its results are left out. The ranking stays by count, as set out in advance, and the rate counts papers, not references.Changes since our letter:
| |||||
| 7 | Noushin NabaviORCID 0000-0002-5471-6229 | 6of 7 found by the census | 16.7%of 36 tagged papers | 6 | 10 |
The 6 papers and 10 citations
Reply from the author, received 21 Oct 2026Dr Nabavi checked the references and passages and accepts that the cited studies have retraction notices and are cited in support of statements in her reviews, but says this does not by itself show prior awareness, misconduct, or that the reviews' overall conclusions are invalid. She notes that her oxaliplatin review was submitted on 21 September 2023, before the cited circPTK2 study was retracted on 18 October 2023, though it was revised and published afterwards. She would need to review the manuscript history before giving an account of awareness, and is willing to work with her co-authors and the journals to assess the affected statements and pursue appropriate corrections. She asked that her entry be deferred until she has seen and answered the human check's findings, and that her response be published alongside her entry; it is printed below as she wrote it. Citation counts alone cannot establish that an entire review is unreliable.Statement from the author, printed as written: Our response: Her dates are exact, and the timeline is printed beside that citation; it stays counted, because every entry is measured by the paper as published. We did not defer her entry, since the list is published whole. If she shows that a reading is wrong, we correct the entry and say so here.Changes since our letter:
| |||||
| 7 | Gautam SethiORCID 0000-0002-8677-8475 | 6of 7 found by the census | 3.1%of 195 tagged papers | 5 | 7 |
The 6 papers and 7 citations
| |||||
| 7 | Chih-Yang HuangORCID 0000-0003-2347-0411 | 6of 6 found by the census | 2.9%of 204 tagged papers | 1 | 6 |
The 6 papers and 6 citations
| |||||
| 7 | Peng LuoORCID 0000-0002-8215-2045 | 6of 6 found by the census | 2.3%of 259 tagged papers | 3 | 6 |
The 6 papers and 6 citations
The published reference list links the retraction notice or labels the work retracted Publishers often add these links and labels during publication, so they do not show that the authors knew.
| |||||
Papers: citing papers with at least one citation the second reading confirmed as support. Rate: those papers as a share of the author's open-access papers in PMC that carry their ORCID iD in Europe PMC, 2010 to 2026 (counted 2026-10-21). The ranking stays by count. The order does not hold under rates, even among the top three: authors with few tagged papers can have high rates on small numbers. Reviews: how many of those papers Europe PMC lists as review articles. Every support citation in every listed author's papers was read again (153 different citations; 217 author items, because the 3 authors who share papers wrote most of them together, so their counts overlap). Ties share a place.
Each listed item names the notice's reason. Results: the notice names a problem with the data, images or results, or says they cannot be relied on. Unclear: it gives no reason or a vague one, or we have not read it yet; these still count. Citations of work retracted only for reasons that do not touch the results are left out, as the census leaves out paperwork retractions. Where a citing paper was submitted or accepted before the retraction, its timeline is printed beside the item; papers that went online before the retraction are left out. 22 of the 200 items sit apart: the citing paper's published reference list links the retraction notice or labels the work retracted, in the reference as the publisher printed it (a retraction link PMC or Europe PMC shows beside a reference is not counted). Such labels and links are often added automatically during publication, so they do not show that the authors knew.
The full ranked tables
Every retracted paper (11,649) and every citing journal (3,807) in the lists' scope, ranked by the citations the census AI models labelled as support, with this page's corrections applied. Only the listed entries and the papers near the last place were read again.
All 11,649 papers (CSV) · All 3,807 journals (CSV) · What the tables hold
Journals and authors below the cut.
These are not ranked. Each was sent its findings on 30 October or 1 November 2026, with until 8 Nov 2026 to reply. They are the entries just below the lists whose citations we read again. Each item is a paper that cites retracted work; under it are the retracted paper it cites and a link to the retraction notice.
Cell Death Discovery Journal · 59 of 117 citations cited as support (50.4%); we read 9 again and 6 held up. Written to 1 Nov 2026.
Reply: none received by 8 Nov 2026.
- Nuclear SPHK2/S1P induces oxidative stress and NLRP3 inflammasome activation via promoting p53 acetylation in lipopolysaccharide-induced acute lung injury. Cell Death Discovery 2023.
- cites Puneet P et al., Science 2010, retracted 26 Jul 2013:
SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis
(notice)
- cites Puneet P et al., Science 2010, retracted 26 Jul 2013:
- Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Cell Death Discovery 2017.
- cites Kumar MS et al., Nature 2014, retracted 10 Jun 2015:
HMGA2 functions as a competing endogenous RNA to promote lung cancer progression
(notice)
- cites Kumar MS et al., Nature 2014, retracted 10 Jun 2015:
- Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis. Cell Death Discovery 2021.
- cites Qu A et al., PLoS One 2014, retracted 17 Dec 2020:
Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer
(notice)
- cites Qu A et al., PLoS One 2014, retracted 17 Dec 2020:
- Long non-coding RNAs and autophagy: dual drivers of Hepatocellular carcinoma progression. Cell Death Discovery 2025.
- cites Chen Y et al., Mol Ther Nucleic Acids 2020, retracted 11 Dec 2022:
LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells
(notice)
- cites Chen Y et al., Mol Ther Nucleic Acids 2020, retracted 11 Dec 2022:
- Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer. Cell Death Discovery 2022.
- cites Zhang B et al., Anat Rec (Hoboken) 2021, retracted 28 Oct 2021:
Alpinumisoflavone triggers GSDME-dependent pyroptosis in esophageal squamous cell carcinomas
(notice) - cites Yin H et al., Anat Rec (Hoboken) 2021, retracted 28 Oct 2021:
Resibufogenin suppresses growth and metastasis through inducing caspase-1-dependent pyroptosis via ROS-mediated NF-κB suppression in non-small cell lung cancer
(notice)
- cites Zhang B et al., Anat Rec (Hoboken) 2021, retracted 28 Oct 2021:
Cells Journal · 152 of 376 citations cited as support (40.4%); we read 10 again and 3 held up. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders. Cells 2020.
- cites Briones TL et al., J Neuroinflammation 2014, retracted 26 Nov 2015:
Chronic neuroinflammation and cognitive impairment following transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling
(notice)
- cites Briones TL et al., J Neuroinflammation 2014, retracted 26 Nov 2015:
- BDNF Modulation by microRNAs: An Update on the Experimental Evidence. Cells 2024.
- cites Zhang J et al., Neurochem Res 2018, retracted 25 Jun 2020:
MicroRNA-322 Cluster Promotes Tau Phosphorylation via Targeting Brain-Derived Neurotrophic Factor
(notice)
- cites Zhang J et al., Neurochem Res 2018, retracted 25 Jun 2020:
- Circular RNA hsa_circ_0008726 Targets the hsa-miR-206-3p/KLF4 Axis to Modulate 4,4'-Methylene Diphenyl Diisocyanate-Glutathione Conjugate-Induced Chemokine Transcription in Macrophages. Cells 2024.
- cites Wang M et al., Onco Targets Ther 2019, retracted 18 May 2022:
Silencing circZFR inhibits the proliferation, migration and invasion of human renal carcinoma cells by regulating miR-206
(notice)
- cites Wang M et al., Onco Targets Ther 2019, retracted 18 May 2022:
Cureus Journal · 136 of 330 citations cited as support (41.2%); we read 8 again and 4 held up. Written to 1 Nov 2026.
Reply (1 Nov 2026): The journal’s support desk answered our letter (1 November) and our reminder (4 November) with automatic notes saying each had been passed to a member of its team. No other reply came by 8 November. In their words: Your request has been reviewed and is being escalated to a member of our team for further assistance.
- Association Between Depression and Medication Adherence Among Post-myocardial Infarction Patients in a South Asian Clinical Setting. Cureus 2025.
- cites Morisky DE et al., J Clin Hypertens 2008, retracted 18 Aug 2023:
Predictive validity of a medication adherence measure in an outpatient setting
(notice)
- cites Morisky DE et al., J Clin Hypertens 2008, retracted 18 Aug 2023:
- Molecular Mechanisms and Treatment Strategies for Helicobacter pylori-Induced Gastric Carcinogenesis and Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Cureus 2024.
- cites Zhou X et al., PLoS One 2014, retracted 22 Oct 2020:
Decreased miR-204 in H. pylori-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4
(notice)
- cites Zhou X et al., PLoS One 2014, retracted 22 Oct 2020:
- Revisional Single-Anastomosis Gastric Bypass for a Patient With Severe Protein-Calorie Malnutrition: A Case Report. Cureus 2023.
- cites Ruiz-Tovar J et al., Surg Endosc 2019, retracted 16 Jan 2021:
Long-term follow-up after sleeve gastrectomy versus Roux-en-Y gastric bypass versus one-anastomosis gastric bypass: a prospective randomized comparative study of weight loss and remission of comorbidities
(notice)
- cites Ruiz-Tovar J et al., Surg Endosc 2019, retracted 16 Jan 2021:
- Postoperative Pain Following Transoral Thyroidectomy via Vestibular Approach and Cervical Thyroidectomy: A Systematic Review and Meta-Analysis. Cureus 2024.
- cites Yang C et al., J Healthc Eng 2022, retracted 4 Oct 2023:
Discussion on the Transoral Vestibular Approach Endoscopy for TC Patients and the Significance of Serum 25-Hydroxyvitamin D Classification
(notice)
- cites Yang C et al., J Healthc Eng 2022, retracted 4 Oct 2023:
Frontiers in Cardiovascular Medicine Journal · 74 of 152 citations cited as support (48.7%); we read 10 again and 6 held up. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- Piperlongumine Attenuates High Calcium/Phosphate-Induced Arterial Calcification by Preserving P53/PTEN Signaling. Frontiers in Cardiovascular Medicine 2020.
- cites Raj L et al., Nature 2011, retracted 25 Jul 2018:
Selective killing of cancer cells by a small molecule targeting the stress response to ROS
(notice)
- cites Raj L et al., Nature 2011, retracted 25 Jul 2018:
- Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications. Frontiers in Cardiovascular Medicine 2023.
- cites Kohrt HE et al., J Clin Invest 2012, retracted 3 Jun 2019:
Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
(notice)
- cites Kohrt HE et al., J Clin Invest 2012, retracted 3 Jun 2019:
- Roles of MicroRNAs in Glucose and Lipid Metabolism in the Heart. Frontiers in Cardiovascular Medicine 2021.
- cites Nagalingam RS et al., J Biol Chem 2013, retracted 24 Mar 2017:
A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling
(notice)
- cites Nagalingam RS et al., J Biol Chem 2013, retracted 24 Mar 2017:
- Epigenetic regulation in myocardial infarction: Non-coding RNAs and exosomal non-coding RNAs. Frontiers in Cardiovascular Medicine 2022.
- cites Kong F et al., Biomed Pharmacother 2019, retracted 9 Dec 2021:
Long noncoding RNA RMRP upregulation aggravates myocardial ischemia-reperfusion injury by sponging miR-206 to target ATG3 expression
(notice)
- cites Kong F et al., Biomed Pharmacother 2019, retracted 9 Dec 2021:
- MicroRNAs as regulators of cardiac dysfunction in sepsis: pathogenesis and diagnostic potential. Frontiers in Cardiovascular Medicine 2025.
- cites Ouyang H et al., Int Immunopharmacol 2020, retracted 21 Feb 2023:
MicroRNA-208-5p regulates myocardial injury of sepsis mice via targeting SOCS2-mediated NF-κB/HIF-1α pathway
(notice)
- cites Ouyang H et al., Int Immunopharmacol 2020, retracted 21 Feb 2023:
- Association of serum coiled-coil domain containing protein 11 levels with coronary artery disease. Frontiers in Cardiovascular Medicine 2026.
- cites Zhou C et al., Onco Targets Ther 2020, retracted 9 Jun 2023:
CCDC7 Activates Interleukin-6 and Vascular Endothelial Growth Factor to Promote Proliferation via the JAK-STAT3 Pathway in Cervical Cancer Cells
(notice)
- cites Zhou C et al., Onco Targets Ther 2020, retracted 9 Jun 2023:
Journal of Cancer Journal · 94 of 187 citations cited as support (50.3%); we read 9 again and 8 held up. Written to 1 Nov 2026.
Reply: none received by 8 Nov 2026.
- Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. Journal of Cancer 2020.
- cites Li Q et al., Mol Immunol 2010, retracted 23 Nov 2011:
A role for the annexin A2 amino-terminal peptide in the plasmin-induced activation of human peripheral monocytes
(notice)
- cites Li Q et al., Mol Immunol 2010, retracted 23 Nov 2011:
- FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/β-catenin Signaling Pathway. Journal of Cancer 2017.
- cites Xing XJ et al., Tumour Biol 2014, retracted 17 Aug 2015:
Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis
(notice)
- cites Xing XJ et al., Tumour Biol 2014, retracted 17 Aug 2015:
- FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility: a review of its function, mechanism, and clinical significance. Journal of Cancer 2022.
- cites Zheng K et al., Oncol Lett 2015, retracted 8 Jul 2021:
MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1
(notice)
- cites Zheng K et al., Oncol Lett 2015, retracted 8 Jul 2021:
- Potential impact and mechanism of Long Non-coding RNAs on cancer and associated T cells. Journal of Cancer 2021.
- cites Fan FY et al., Int J Oncol 2017, retracted 22 Dec 2020:
The inhibitory effect of MEG3/miR-214/AIFM2 axis on the growth of T-cell lymphoblastic lymphoma
(notice)
- cites Fan FY et al., Int J Oncol 2017, retracted 22 Dec 2020:
- Prognostic Value and Immune Landscapes of Four Types of RNA Modification Writer-Related LncRNAs Signature in Lung Adenocarcinoma. Journal of Cancer 2024.
- cites Xiu DH et al., J Exp Clin Cancer Res 2019, retracted 27 Oct 2021:
Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2
(notice)
- cites Xiu DH et al., J Exp Clin Cancer Res 2019, retracted 27 Oct 2021:
- Circular RNA circASPM promotes the progression of glioblastoma by acting as a competing endogenous RNA to regulate miR-130b-3p/E2F1 axis. Journal of Cancer 2022.
- cites Xie Y et al., Eur Rev Med Pharmacol Sci 2019, retracted Jul 2020:
Long noncoding RNA CASC15 is upregulated in glioma and facilitates cell proliferation and metastasis via targeting miR-130b-3p
(notice)
- cites Xie Y et al., Eur Rev Med Pharmacol Sci 2019, retracted Jul 2020:
- MiR-675 Inhibits Primary Ovarian Tumor Growth and Metastasis by Suppressing EMT and TGFβ Signaling. Journal of Cancer 2025.
- cites Wang J et al., Onco Targets Ther 2019, retracted 4 Oct 2021:
MicroRNA-675 directly targets MAPK1 to suppress the oncogenicity of papillary thyroid cancer and is sponged by long non-coding RNA RMRP
(notice)
- cites Wang J et al., Onco Targets Ther 2019, retracted 4 Oct 2021:
- FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma. Journal of Cancer 2024.
- cites Le Y et al., Comput Math Methods Med 2022, retracted 29 Nov 2023:
Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining
(notice)
- cites Le Y et al., Comput Math Methods Med 2022, retracted 29 Nov 2023:
Medicine Journal · 160 of 380 citations cited as support (42.1%); we read 9 again and 7 held up. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- Association between PTGER4 polymorphisms and inflammatory bowel disease risk in Caucasian: A meta-analysis. Medicine 2020.
- cites Subbaramaiah K et al., J Biol Chem 2004, retracted 3 Jan 2020:
Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1
(notice)
- cites Subbaramaiah K et al., J Biol Chem 2004, retracted 3 Jan 2020:
- Mining and validating the expression pattern and prognostic value of acetylcholine receptors in non-small cell lung cancer. Medicine 2019.
- cites Paleari L et al., Cell Prolif 2008, retracted 29 Aug 2017:
Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation
(notice)
- cites Paleari L et al., Cell Prolif 2008, retracted 29 Aug 2017:
- Genetically confirmed limb-girdle muscular dystrophy type 2B with DYSF mutation using gene panel sequencing: A case report. Medicine 2020.
- cites Azakir BA et al., J Biol Chem 2012, retracted 28 Jul 2017:
Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells
(notice)
- cites Azakir BA et al., J Biol Chem 2012, retracted 28 Jul 2017:
- Central metabolites and peripheral parameters associated neuroinflammation in fibromyalgia patients: A preliminary study. Medicine 2023.
- cites Briones TL et al., Acta Neuropathol Commun 2013, retracted 17 May 2022:
Decreased neuroinflammation and increased brain energy homeostasis following environmental enrichment after mild traumatic brain injury is associated with improvement in cognitive function
(notice)
- cites Briones TL et al., Acta Neuropathol Commun 2013, retracted 17 May 2022:
- Effect of miR-145 on intracardiac thrombosis in patients with rheumatic heart disease complicated with atrial fibrillation: A retrospective analysis. Medicine 2023.
- cites Li L et al., Phytother Res 2020, retracted 7 Aug 2020:
Baicalin relieves TNF-α-evoked injury in human aortic endothelial cells by up-regulation of miR-145
(notice)
- cites Li L et al., Phytother Res 2020, retracted 7 Aug 2020:
- A bibliometric analysis of the published studies in ciprofol research. Medicine 2025.
- cites Ludbrook G et al., Anesth Analg 2021, retracted 15 Jun 2021:
Assessments of Onset and Duration of Drug Effects and Pharmacokinetics by Dose Level of HSK3486, a New Sedative-Hypnotic Agent, in Healthy Female/Male Subjects: A Phase I Multiarm Randomized Controlled Clinical Trial
(notice) The reference list marks it retracted.
- cites Ludbrook G et al., Anesth Analg 2021, retracted 15 Jun 2021:
- Effect of ultrasound-guided nerve blocks on anesthesia and pulmonary function in patients undergoing distal radius fracture surgery. Medicine 2024.
- cites Cai Q et al., J Healthc Eng 2022, retracted 4 Oct 2023:
Analysis of the Effect of Applying Ultrasound-Guided Nerve Block Anesthesia to Fracture Patients in the Context of Internet-Based Blockchain
(notice)
- cites Cai Q et al., J Healthc Eng 2022, retracted 4 Oct 2023:
Oncology Reports Journal · 51 of 109 citations cited as support (46.8%); we read 7 again and 6 held up. Written to 1 Nov 2026.
Reply: none received by 8 Nov 2026.
- Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells. Oncology Reports 2019.
- cites Vaid M et al., PLoS One 2011, retracted 31 Dec 2018:
Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells
(notice)
- cites Vaid M et al., PLoS One 2011, retracted 31 Dec 2018:
- Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review). Oncology Reports 2021.
- cites Feng SD et al., Onco Targets Ther 2017, retracted 9 Mar 2020:
Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma
(notice)
- cites Feng SD et al., Onco Targets Ther 2017, retracted 9 Mar 2020:
- Biological functions and potential mechanisms of miR‑143‑3p in cancers (Review). Oncology Reports 2024.
- cites Ding X et al., Onco Targets Ther 2019, retracted 6 Apr 2023:
MicroRNA-143-3p suppresses tumorigenesis by targeting catenin-δ1 in colorectal cancer
(notice) - cites Sun F et al., Onco Targets Ther 2020, retracted 11 Sep 2023:
Long Noncoding RNA PVT1 Promotes Prostate Cancer Metastasis by Increasing NOP2 Expression via Targeting Tumor Suppressor MicroRNAs
(notice)
- cites Ding X et al., Onco Targets Ther 2019, retracted 6 Apr 2023:
- Epigenetic regulation of mRNA mediates the phenotypic plasticity of cancer cells during metastasis and therapeutic resistance (Review). Oncology Reports 2024.
- cites Cheng C et al., Mol Ther Nucleic Acids 2021, retracted 5 Oct 2023:
METTL3-mediated m6A modification of ZBTB4 mRNA is involved in the smoking-induced EMT in cancer of the lung
(notice) Received 8 Sep 2023, retraction notice 5 Oct 2023, published online 19 Dec 2023.
- cites Cheng C et al., Mol Ther Nucleic Acids 2021, retracted 5 Oct 2023:
- NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia. Oncology Reports 2023.
- cites Sun X et al., J Healthc Eng 2022, retracted 28 Dec 2022:
MiR-483 Promotes Colorectal Cancer Cell Biological Progression by Directly Targeting NDRG2 through Regulation of the PI3K/AKT Signaling Pathway and Epithelial-to-Mesenchymal Transition
(notice) Received 3 Nov 2022, retraction notice 28 Dec 2022, published online 16 Jun 2023.
- cites Sun X et al., J Healthc Eng 2022, retracted 28 Dec 2022:
Oncotarget Journal · 142 of 388 citations cited as support (36.6%); we read 9 again and 4 held up. Written to 1 Nov 2026.
Reply (4 Nov 2026): The journal’s Scientific Integrity Office said it is reviewing the information and will look into these citations. In their words: We are reviewing the information provided and will look into these citations.
- Transcriptional repression of FOXO1 by KLF4 contributes to glioma progression. Oncotarget 2016.
- cites Bois PR et al., J Cell Biol 2005, retracted 7 May 2007:
FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma
(notice)
- cites Bois PR et al., J Cell Biol 2005, retracted 7 May 2007:
- Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2. Oncotarget 2016.
- cites Valastyan S et al., Cancer Res 2010, retracted 30 Jun 2015:
Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis
(notice)
- cites Valastyan S et al., Cancer Res 2010, retracted 30 Jun 2015:
- Epithelial-to-mesenchymal transition in the development of endometriosis. Oncotarget 2017.
- cites Jia J et al., PLoS One 2012, retracted 10 Sep 2014:
Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma
(notice)
- cites Jia J et al., PLoS One 2012, retracted 10 Sep 2014:
- STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget 2016.
- cites Kumar MS et al., Nature 2014, retracted 10 Jun 2015:
HMGA2 functions as a competing endogenous RNA to promote lung cancer progression
(notice)
- cites Kumar MS et al., Nature 2014, retracted 10 Jun 2015:
Agnieszka Rak Author · 3 citations in 3 of their papers held up on a second reading. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- Visfatin impact on the proteome of porcine luteal cells during implantation. Scientific Reports 2024.
- cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007:
Visfatin: a protein secreted by visceral fat that mimics the effects of insulin
(notice)
- cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007:
- Visfatin (NAMPT) affects global gene expression in porcine anterior pituitary cells during the mid-luteal phase of the oestrous cycle. Journal of Animal Science and Biotechnology 2024.
- cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007:
Visfatin: a protein secreted by visceral fat that mimics the effects of insulin
(notice)
- cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007:
- Visfatin exerts an anti-proliferative and pro-apoptotic effect in the human placenta cells. Biology of Reproduction 2025.
- cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007:
Visfatin: a protein secreted by visceral fat that mimics the effects of insulin
(notice)
- cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007:
Ali Zarrabi Author · 6 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Life 2020.
- cites Malhotra D et al., Am J Respir Crit Care Med 2009, retracted 1 Feb 2016:
Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity
(notice)
- cites Malhotra D et al., Am J Respir Crit Care Med 2009, retracted 1 Feb 2016:
- The long and short non-coding RNAs modulating EZH2 signaling in cancer. Journal of Hematology & Oncology 2022.
- cites Zhu F et al., J Cell Biochem 2018, retracted 9 Jun 2021:
LncRNA AWPPH inhibits SMAD4 via EZH2 to regulate bladder cancer progression
(notice) - cites Pan MZ et al., Eur Rev Med Pharmacol Sci 2019, retracted 10 Mar 2021:
MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2
(notice) - cites Zheng W et al., Cancer Manag Res 2020, retracted 18 Sep 2021:
microRNA-26a Directly Targeting MMP14 and MMP16 Inhibits the Cancer Cell Proliferation, Migration and Invasion in Cutaneous Squamous Cell Carcinoma
(notice)
- cites Zhu F et al., J Cell Biochem 2018, retracted 9 Jun 2021:
- Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. Journal of Hematology & Oncology 2022.
- cites Wu J et al., Hepatology 2021, retracted 1 Dec 2021:
M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α(M) β(2) Integrin to Tumor Cells
(notice)
- cites Wu J et al., Hepatology 2021, retracted 1 Dec 2021:
- Lipid-Based Delivery Systems for Flavonoids and Flavonolignans: Liposomes, Nanoemulsions, and Solid Lipid Nanoparticles. Pharmaceutics 2023.
- cites Li P et al., Int J Nanomedicine 2020, retracted 4 Aug 2022:
Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway
(notice)
- cites Li P et al., Int J Nanomedicine 2020, retracted 4 Aug 2022:
Learn-Han Lee Author · 1 citation in 1 of their papers held up on a second reading. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. Cancers 2022.
- cites Pedrero JM et al., Int J Cancer 2005, retracted 6 May 2019:
Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma
(notice) The reference list marks it retracted.
- cites Pedrero JM et al., Int J Cancer 2005, retracted 6 May 2019:
Mariusz Jaremko Author · 12 citations in 5 of their papers held up on a second reading. Written to 1 Nov 2026.
Reply (1 Nov 2026): Dr Jaremko objects to being listed and to having his replies quoted or summarised. He says the papers are joint work by several authors and asks that any paper wrongly attributed to him be removed. He says he may take legal action. In their words: I reserve all my rights to pursue appropriate legal remedies, including proceedings before the competent courts and, where applicable, a complaint to the relevant data protection supervisory authority.
- Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer. Molecules 2024.
- cites Akbarzadeh A et al., J Nanobiotechnology 2012, retracted 19 Jan 2019:
Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line
(notice) - cites Wang JY et al., ACS Omega 2020, retracted 19 Jul 2021:
Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy
(notice)
- cites Akbarzadeh A et al., J Nanobiotechnology 2012, retracted 19 Jan 2019:
- Fungal Endophytes: Microfactories of Novel Bioactive Compounds with Therapeutic Interventions; A Comprehensive Review on the Biotechnological Developments in the Field of Fungal Endophytic Biology over the Last Decade. Biomolecules 2023.
- cites Mishra VK et al., PLoS One 2017, retracted 26 May 2022:
Determination and production of antimicrobial compounds by Aspergillus clavatonanicus strain MJ31, an endophytic fungus from Mirabilis jalapa L. using UPLC-ESI-MS/MS and TD-GC-MS analysis
(notice)
- cites Mishra VK et al., PLoS One 2017, retracted 26 May 2022:
- Novel Copper Oxide Bio-Nanocrystals to Target Outer Membrane Lectin of Vancomycin-Resistant Enterococcus faecium (VREfm): In Silico, Bioavailability, Antimicrobial, and Anticancer Potential. Molecules 2022.
- cites Maqbool Q et al., Front Pharmacol 2018, retracted 7 Feb 2019:
CuO and CeO2 Nanostructures Green Synthesized Using Olive Leaf Extract Inhibits the Growth of Highly Virulent Multidrug Resistant Bacteria
(notice)
- cites Maqbool Q et al., Front Pharmacol 2018, retracted 7 Feb 2019:
- Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review. ACS Pharmacology & Translational Science 2024.
- cites Qu Y et al., J Cell Physiol 2019, retracted 20 Jul 2021:
Downregulated microRNA-135a ameliorates rheumatoid arthritis by inactivation of the phosphatidylinositol 3-kinase/AKT signaling pathway via phosphatidylinositol 3-kinase regulatory subunit 2
(notice) - cites Li D et al., Biosci Rep 2019, retracted 28 Jul 2021:
MiRNA-506 inhibits rheumatoid arthritis fibroblast-like synoviocytes proliferation and induces apoptosis by targetting TLR4
(notice) - cites Qiang J et al., Biosci Rep 2019, retracted 1 Sep 2020:
Down-regulation of microRNA-142-3p inhibits the aggressive phenotypes of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting nuclear factor-κB signaling
(notice) - cites Wei Q et al., Biosci Rep 2020, retracted 4 Aug 2020:
MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2
(notice) - cites Hu X et al., Mol Ther Nucleic Acids 2020, retracted 13 May 2022:
Silencing of Long Non-coding RNA HOTTIP Reduces Inflammation in Rheumatoid Arthritis by Demethylation of SFRP1
(notice) - cites Huang Y et al., Cell Cycle 2020, retracted 21 Jun 2022:
Up-regulated microRNA-411 or declined RIPK1 inhibits proliferation and promotes apoptosis of synoviocytes in rheumatoid arthritis mice via decreased NF-κB pathway
(notice) - cites Wang ZQ et al., J Clin Lab Anal 2020, retracted 6 Dec 2021:
Long non-coding RNA XIST binding to let-7c-5p contributes to rheumatoid arthritis through its effects on proliferation and differentiation of osteoblasts via regulation of STAT3
(notice)
- cites Qu Y et al., J Cell Physiol 2019, retracted 20 Jul 2021:
- Deciphering the therapeutic potential of trimetazidine in rheumatoid arthritis via targeting mi-RNA128a, TLR4 signaling pathway, and adenosine-induced FADD-microvesicular shedding: In vivo and in silico study. Frontiers in Pharmacology 2024.
- cites Zhang X et al., Contrast Media Mol Imaging 2022, retracted 19 Jul 2023:
Investigation on the Inhibitory Effect of Methotrexate on Rheumatoid Synovitis via the TLR4-NF-κB Pathway in a Rat Model
(notice)
- cites Zhang X et al., Contrast Media Mol Imaging 2022, retracted 19 Jul 2023:
Sachin Kumar Singh Author · 3 citations in 3 of their papers held up on a second reading. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- Implications of reactive oxygen species in lung cancer and exploiting it for therapeutic interventions. Medical Oncology 2022.
- cites Raj L et al., Nature 2011, retracted 25 Jul 2018:
Selective killing of cancer cells by a small molecule targeting the stress response to ROS
(notice)
- cites Raj L et al., Nature 2011, retracted 25 Jul 2018:
- Unlocking the power of nanomedicine: the future of nutraceuticals in oncology treatment. Frontiers in Nutrition 2023.
- cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021:
Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade
(notice) The reference list marks it retracted.
- cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021:
- Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis. CNS Neuroscience & Therapeutics 2024.
- cites Dong X et al., Dis Markers 2022, retracted 2 Aug 2023:
Inhibition of miR-421 Preserves Mitochondrial Function and Protects against Parkinson's Disease Pathogenesis via Pink1/Parkin-Dependent Mitophagy
(notice)
- cites Dong X et al., Dis Markers 2022, retracted 2 Aug 2023:
Samy Selim Author · 5 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies. Food Science & Nutrition 2025.
- cites Patil SP et al., Neuropharmacology 2014, retracted 9 Nov 2021:
Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice
(notice)
- cites Patil SP et al., Neuropharmacology 2014, retracted 9 Nov 2021:
- Isoflavones: Promising Natural Agent for Cancer Prevention and Treatment. Food Science & Nutrition 2025.
- cites Xiao P et al., Oncol Lett 2017, retracted 12 Apr 2021:
Biochanin A induces anticancer effects in SK-Mel-28 human malignant melanoma cells via induction of apoptosis, inhibition of cell invasion and modulation of NF-kB and MAPK signaling pathways
(notice) The reference list marks it retracted. - cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021:
Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade
(notice) The reference list marks it retracted.
- cites Xiao P et al., Oncol Lett 2017, retracted 12 Apr 2021:
- Recent Perspectives on Anticancer Potential of Coumarin Against Different Human Malignancies: An Updated Review. Food Science & Nutrition 2025.
- cites Dong L et al., Oncol Rep 2018, retracted 26 Apr 2021:
In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrial-mediated apoptosis, cell cycle arrest, and inhibition of cancer cell migration
(notice)
- cites Dong L et al., Oncol Rep 2018, retracted 26 Apr 2021:
- Novel Copper Oxide Bio-Nanocrystals to Target Outer Membrane Lectin of Vancomycin-Resistant Enterococcus faecium (VREfm): In Silico, Bioavailability, Antimicrobial, and Anticancer Potential. Molecules 2022.
- cites Maqbool Q et al., Front Pharmacol 2018, retracted 7 Feb 2019:
CuO and CeO2 Nanostructures Green Synthesized Using Olive Leaf Extract Inhibits the Growth of Highly Virulent Multidrug Resistant Bacteria
(notice)
- cites Maqbool Q et al., Front Pharmacol 2018, retracted 7 Feb 2019:
Shafiul Haque Author · 7 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.
Reply: none received by 8 Nov 2026.
- Serum Cytokine Profile in Patients with Chronic Rhinosinusitis with Nasal Polyposis Infected by Aspergillus flavus. Annals of Laboratory Medicine 2018.
- cites Radhakrishnan S et al., J Immunol 2008, retracted 1 Jun 2010:
Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo
(notice)
- cites Radhakrishnan S et al., J Immunol 2008, retracted 1 Jun 2010:
- Roles of HOTAIR Long Non-coding RNA in Gliomas and Other CNS Disorders. Cellular and Molecular Neurobiology 2024.
- cites Sa L et al., Front Mol Neurosci 2017, retracted 2 May 2023:
The Role of HOTAIR/miR-148b-3p/USF1 on Regulating the Permeability of BTB
(notice) - cites Zhao W et al., Cancer Med 2018, retracted 15 Dec 2023:
LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer
(notice) Received 15 Jun 2023, retraction notice 15 Dec 2023, published online 16 Feb 2024. - cites Wang Z et al., Comput Math Methods Med 2022, retracted 6 Dec 2023:
lncRNA HOTAIR Inhibition by Regulating HMGB1/ROS/NF-κB Signal Pathway Promotes the Recovery of Spinal Cord Function
(notice) Received 15 Jun 2023, retraction notice 6 Dec 2023, published online 16 Feb 2024.
- cites Sa L et al., Front Mol Neurosci 2017, retracted 2 May 2023:
- The multifaceted functions of long non-coding RNA HOTAIR in neuropathologies and its potential as a prognostic marker and therapeutic biotarget. Expert Reviews in Molecular Medicine 2024.
- cites Sa L et al., Front Mol Neurosci 2017, retracted 2 May 2023:
The Role of HOTAIR/miR-148b-3p/USF1 on Regulating the Permeability of BTB
(notice) - cites Wang Z et al., Comput Math Methods Med 2022, retracted 6 Dec 2023:
lncRNA HOTAIR Inhibition by Regulating HMGB1/ROS/NF-κB Signal Pathway Promotes the Recovery of Spinal Cord Function
(notice) Received 5 Sep 2023, retraction notice 6 Dec 2023, published online 29 Apr 2024.
- cites Sa L et al., Front Mol Neurosci 2017, retracted 2 May 2023:
- Gut Microbiota-Assisted Synthesis, Cellular Interactions and Synergistic Perspectives of Equol as a Potent Anticancer Isoflavone. Pharmaceuticals 2022.
- cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021:
Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade
(notice)
- cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021:
Zodwa Dlamini Author · 5 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.
Reply (6 Nov 2026): Professor Dlamini confirmed the five citations across the four reviews, said the journals had not flagged the retractions at any stage, and noted that the Genes 2022 review was submitted on 13 December 2021, a week before the cited study was retracted. In their words: the absence of such acknowledgement should not be interpreted as evidence that the authors knowingly cited retracted research
- Reports of Plant-Derived Nanoparticles for Prostate Cancer Therapy. Plants 2023.
- cites Pulukuri SM et al., J Biol Chem 2005, retracted 11 Sep 2020:
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo
(notice)
- cites Pulukuri SM et al., J Biol Chem 2005, retracted 11 Sep 2020:
- The Role of MicroRNAs in Kidney Disease. Non-Coding RNA 2015.
- cites Gupta A et al., PLoS One 2011, retracted 29 Aug 2012:
Comparative expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells infected with human immunodeficiency virus (HIV-1)
(notice)
- cites Gupta A et al., PLoS One 2011, retracted 29 Aug 2012:
- MicroRNA Interrelated Epithelial Mesenchymal Transition (EMT) in Glioblastoma. Genes 2022.
- cites Zhang C et al., J Exp Clin Cancer Res 2017, retracted 20 Dec 2021:
TGF-β2 initiates autophagy via Smad and non-Smad pathway to promote glioma cells' invasion
(notice) Received 13 Dec 2021, retraction notice 20 Dec 2021, published online 27 Jan 2022.
- cites Zhang C et al., J Exp Clin Cancer Res 2017, retracted 20 Dec 2021:
- Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues. Non-coding RNA Research 2024.
- cites Zhang W et al., Int J Oncol 2018, retracted 21 Nov 2022:
Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer
(notice) - cites Kang M et al., J Exp Clin Cancer Res 2018, retracted 6 Apr 2023:
Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA
(notice)
- cites Zhang W et al., Int J Oncol 2018, retracted 21 Nov 2022:
Counted by the census, then read again.
How these lists were checked
- Papers
- Every citation counted as support was read again in full (23 Oct 2026) for each listed paper and each paper near the last place, 21 papers in all. For the 8 nearest the last place, each citation was read twice, independently, and a third reading settled any disagreement. The 2 papers left off after reading were judged on their second reading, not read in full.
- Journals
- A random sample of 7 to 10 support citations per journal was read again, not every citation.
- Authors
- Every support citation in every listed author's papers was read again (153 different citations; 217 author items, because the 3 authors who share papers wrote most of them together, so their counts overlap).
All of these are AI readings.
Everyone named was written to before publication, sent the evidence and asked to tell us if a reading is wrong. Replies received by the date in each letter (28 October, 30 October) (5 on the page so far; all replies) are summarised and quoted beside their entries; the 2 statements written for publication are printed as written.
- AI readings.Each label is our reading of a published passage by the method on this page, and each paper and author item links to its passages so you can judge it yourself. The counts come from the Phase 2 census: three AI models read every citing passage. Each list was then checked again, as set out in the box at the top; those are AI readings too. Everyone named was sent the evidence and asked to tell us if a reading is wrong; where one is, we correct the entry and say so beside it.
- Dates and reasons from the notice.Each retraction date and reason on the lists comes from the journal's retraction notice, not from a database. Where we have not yet read a notice, we say so instead of giving a reason. Corrections made after the data was built are listed, with their sources, in list_corrections.json.
- What each paper reached.For every paper the census found citing a listed paper as support after its retraction, we read its Europe PMC record on 29 October 2026: its publication type (review, systematic review, trial) and the grants it acknowledges. "In turn" counts the distinct later papers that cite any of those papers, for any reason, with the systematic reviews, trials and guidelines among them as Europe PMC types them; it measures reach, not harm. Registered trials are ClinicalTrials.gov records first submitted after the retraction that list the retracted paper among their references. Totals are in reach.json.
- Followed by reading.For a paper we could follow, we took one of its most-cited supporting papers that repeats the retracted claim, then searched Europe PMC for later papers that cite it and mention the same topic. In every one we could read in full (among the first 100 search results), we found the sentence that cites it and judged by hand whether that sentence repeats the retracted claim. A search word can match a sentence that says the opposite, so no count rests on the word alone.
- Only citations made after the retraction.A citation counts if the citing paper came out after the retraction. That means it first went online on or after the earliest date we hold for the retraction (the notice's PubMed, Crossref or Retraction Watch date), compared to the day; papers submitted or accepted before the notice carry their timeline. Until 9 Nov 2026 we compared calendar years except where we had checked dates one by one; citations by papers that went online before the retraction are now left out, each listed in list_corrections.json.
- Only retractions about the results.Citations of a paper are left out when its retraction notice gives only reasons that do not touch the results, such as reused text, a duplicate of a result that stays published, authorship, ethics paperwork, copyright or a software licence, or a wrong journal; the census already leaves out paperwork retractions the same way. We apply this where we have read the notice. A notice that gives no reason, or an unclear one, still counts and is marked "reason unclear". They are not hidden: 289 later citations cite 20 such papers as support, from 289 citing papers. The papers · every citation, labelled with the reason.
- Only confirmed retractions.The lists use only papers PubMed links to a retraction notice: 45,467 judged citations to 11,649 retracted papers. Papers replaced by a corrected version, and paperwork retractions that find no fault in the science, are left out.
- Authors by ORCID only.Authors are matched by their ORCID iD, so two people with the same name are never merged. Authors without an ORCID iD in Europe PMC cannot be listed, so this is not every author.
- What the second reading found.Of 599 different citations the census called support and we read again, 511 (85.3%) held up after every reading. 58 only mentioned the paper in passing, 7 flagged it as retracted or unreliable, and 23 were about something else, most often because the reference pointed at the wrong paper. These citations come from the top of each list, so they are not a rate for the whole census. The file lists the 454 that belong to entries on this page; the rest belong to places below the cut and are kept back. Some papers were cited only for a tool or method that still works; those are left off, with the reason shown.
- Open-access papers only.The census reads papers whose full text is open in Europe PMC. Journals that publish everything open access are counted in full, others only in part, so the counts favour large open-access journals.
- Check it yourself.Each list as a CSV: papers · journals by count · journals by share · authors. every author item, with the notice's reason class and any timeline. Every citation read again, with its verdict and a note. Every reply from the people named, as summarised. What each column means.
- The full tables.All 11,649 retracted papers and all 3,807 citing journals. They are ranked by count with the corrections in list_corrections.json applied: 290 papers' counts differ from the census labels alone, and the file gives both. Only the listed entries and the papers near the last place were read again. All papers · all journals · PubMed retraction status of every paper. Their reason column is grouped from Retraction Watch codes, not the notice's wording.
- Corrections.If you are named and think an entry is wrong, write to SaneCite at letters@sanecite.com, with the citing paper's PMC number if you have it. We reply within two working days and decide within seven days. A correction is made beside the entry, dated, and logged in list_corrections.json. You can also ask us to take an entry down: it comes off when the evidence shows a reading is wrong or a citation is out of scope, the same rule for everyone, and if it stays we tell you why.
What we hold about the people named, and why.
- Who is responsible.SaneCite, an independent research project in Georgia, USA. To reach us, write to SaneCite at letters@sanecite.com.
- What we use.Names, ORCID iDs and publication records: titles, journals, dates, reference lists and the passages that cite retracted work. And the replies people send us.
- Where it comes from.Public records: Europe PMC (with the ORCID iDs it holds), PubMed, the Retraction Watch database and the journals' own retraction notices.
- Why, and on what basis.Research in the public interest on how the published record handles retracted work, and publishing its results. Where UK or European data protection law applies, we rely on legitimate interests in research and free expression, and on the exemptions those laws give to academic and journalistic work. Entries come from whole-set counts, never picked by hand.
- How entries are made.By AI readings of the citing passages, by the method on this page, with a right of reply for the people named before publication.
- What we print from a reply.A summary in our words, one short quote, and any statement written for publication, the same for everyone. From 2 November 2026, a reply that threatens legal action or a complaint to a regulator is printed in full beside the entry. We never print email addresses, phone numbers or details about other people. Any other full reply is kept privately and shared only when needed, with a journal, a fiscal sponsor or a lawyer.
- How long.Published entries stay as part of the research record, with every correction dated. Private correspondence is kept while the entry is published and for two years after.
- Your rights.You can ask us to correct your entry, to tell you what we hold about you, to restrict or stop a use, or to delete what we hold: write to SaneCite at letters@sanecite.com. We reply within two working days and decide within one month. Where we keep a published entry because the research record needs it, we tell you why. You can also complain to your data protection authority (in the UK, the Information Commissioner's Office).